These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 27929198)
21. Fibrin clot properties and haemostatic function in men and women with type 1 diabetes. Tehrani S; Jörneskog G; Ågren A; Lins PE; Wallén H; Antovic A Thromb Haemost; 2015 Feb; 113(2):312-8. PubMed ID: 25318636 [TBL] [Abstract][Full Text] [Related]
22. Reduced Plasma Magnesium Levels in Type-1 Diabetes Associate with Prothrombotic Changes in Fibrin Clotting and Fibrinolysis. Sobczak AIS; Phoenix FA; Pitt SJ; Ajjan RA; Stewart AJ Thromb Haemost; 2020 Feb; 120(2):243-252. PubMed ID: 31942750 [TBL] [Abstract][Full Text] [Related]
23. Aspirin therapy is associated with less compact fibrin networks and enhanced fibrinolysis in patients with abdominal aortic aneurysm. Bailey MA; Aggarwal R; Bridge KI; Griffin KJ; Iqbal F; Phoenix F; Purdell-Lewis J; Thomas T; Johnson AB; Ariëns RA; Scott DJ; Ajjan RA J Thromb Haemost; 2015 May; 13(5):795-801. PubMed ID: 25660763 [TBL] [Abstract][Full Text] [Related]
24. The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis. Collet JP; Moen JL; Veklich YI; Gorkun OV; Lord ST; Montalescot G; Weisel JW Blood; 2005 Dec; 106(12):3824-30. PubMed ID: 16091450 [TBL] [Abstract][Full Text] [Related]
33. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots. Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724 [TBL] [Abstract][Full Text] [Related]
34. Enhanced lysis and accelerated establishment of viscoelastic properties of fibrin clots are associated with pulmonary embolism. Martinez MR; Cuker A; Mills AM; Crichlow A; Lightfoot RT; Chernysh IN; Nagaswami C; Weisel JW; Ischiropoulos H Am J Physiol Lung Cell Mol Physiol; 2014 Mar; 306(5):L397-404. PubMed ID: 24414255 [TBL] [Abstract][Full Text] [Related]
35. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. Sauls DL; Wolberg AS; Hoffman M J Thromb Haemost; 2003 Feb; 1(2):300-6. PubMed ID: 12871504 [TBL] [Abstract][Full Text] [Related]
36. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Carter AM; Cymbalista CM; Spector TD; Grant PJ; Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2783-9. PubMed ID: 17932316 [TBL] [Abstract][Full Text] [Related]
37. Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice. Ząbczyk M; Ariëns RAS; Undas A Cardiovasc Res; 2023 Mar; 119(1):94-111. PubMed ID: 36662542 [TBL] [Abstract][Full Text] [Related]
38. Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism. Owczarek D; Cibor D; Sałapa K; Głowacki MK; Mach T; Undas A Inflamm Bowel Dis; 2013 Nov; 19(12):2616-24. PubMed ID: 24108112 [TBL] [Abstract][Full Text] [Related]
39. Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications. Kearney KJ; Pechlivani N; King R; Tiede C; Phoenix F; Cheah R; Macrae FL; Simmons KJ; Manfield IW; Smith KA; Spurgeon BEJ; Naseem KM; Ariens RAS; McPherson MJ; Tomlinson DC; Ajjan RA Blood; 2019 Mar; 133(11):1233-1244. PubMed ID: 30545831 [TBL] [Abstract][Full Text] [Related]
40. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Undas A; Kaczmarek P; Sladek K; Stepien E; Skucha W; Rzeszutko M; Gorkiewicz-Kot I; Tracz W Thromb Haemost; 2009 Dec; 102(6):1176-82. PubMed ID: 19967149 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]